Consolidation of AML Therapy with Autograft and Allograft Procedures Does not Negate the Poor Prognostic Impact of FLT-3 Internal Tandem Duplications: Results for UK MRC AML 10 and 12 Trials.

Reviewer: Julie Draznin Maltzman, MD
Ultima Vez Modificado: 9 de diciembre del 2002

Translation for this article does not exist


Where Are the Adults in the Room?
by Rodney Warner, JD
November 20, 2015

Related News

Addition of Gemtuzumab Ozogamicin Ups Survival in AML

Apr 9, 2012

Phase 3 trial shows improved event-free, overall survival versus standard therapy alone

Azacitidine Treatment Effective in Previously Untreated AML

Jul 26, 2011

Better response rate for previously untreated patients, those with WBC count of <10 × 109/L

Specific Mutations in AML Affect Response to Therapy

Mar 15, 2012

Also, bone marrow cells in myelodysplastic syndromes, secondary AML are clonal